A concentrated preparation of unroasted coffee beans that, unless decaffeinated, carries a caffeine load. Pooled human trials show small reductions in body weight, waist size, blood pressure, fasting blood sugar and cholesterol — real, but too small to notice without measurement and seen over weeks to months, not years. Product quality varies more than the compound itself. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Home blood pressure | 110–120 / 70–78 mmHg | The most reproducible benefit; also detects overshoot |
| Fasting glucose | 75–86 mg/dL | Direct target of the intestinal and liver mechanism |
| Fasting insulin | 2–5 μU/mL | Detects the effect seen only at doses of 400 mg daily or more |
| Glycated hemoglobin | 4.9–5.3% | Confirms whether small fasting glucose shifts persist |
| LDL-C and HDL-C | LDL-C below 80 mg/dL; HDL-C 55–80 mg/dL | Tracks the documented small lipid shift |
| Plasma total homocysteine | 5–7 μmol/L | The one marker this compound is documented to worsen |
| Alanine and aspartate aminotransferase | 10–26 U/L for each | Baseline for attributing any later rise, given supplement liver injury reports |
| High-sensitivity C-reactive protein | Below 0.55 mg/L | The inflammation signal is conflicted; a personal reading resolves it |
| Waist circumference | Below 94 cm (men) / 80 cm (women) | Where the pooled body-size effect is most consistent |
| Serum ferritin | 50–100 ng/mL (women); 50–150 ng/mL (men) | Detects any decline in iron stores from polyphenol binding |
Cadence: Home blood pressure repeated at 4 weeks; full panel at 12 weeks, then every 6–12 months while use continues; weight and waist circumference recorded monthly